SEC Form 4 · accession 0000899243-18-029124
EyePoint, Inc. · EYPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael W Rogers
Director
Period of report
Nov 15, 2018
Accepted (ET)
Nov 16, 2018 · 4:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314102
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 15, 2018 | M | 100,000 | $1.13 | A | 112,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $1.13 | Nov 15, 2018 | M | 100,000 | D | Nov 18, 2009 | Nov 18, 2018 | Common Stock | 100,000 | 0 | D |
Explanation of responses
- F1Consists of (i) 100,000 shares of common stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc. (the "Company") acquired upon exercise of the stock option as described above and (ii) 12,500 shares of common stock of the Company underlying certain deferred stock units ("DSUs") previously awarded to the reporting person, with each DSU representing the right to receive one share of common stock of the Company. These DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986,